Literature DB >> 11166239

From evil to good: a cytolysin in vaccine development.

G Dietrich1, J Hess, I Gentschev, B Knapp, S H Kaufmann, W Goebel.   

Abstract

Current vaccination strategies mainly target antigens into the phagosomal, major histocompatibility complex class II antigen-processing pathway and thus lead predominantly to humoral immune responses. The elicitation of cytotoxic T-cell responses instead requires introduction of antigens into the cytosol of professional antigen-presenting cells (APCs). The intracellular bacterium Listeria monocytogenes gains access to the host cell cytosol by means of a cytolysin, listeriolysin O. Vaccine researchers have successfully employed listeriolysin in novel vaccination approaches to provide access to the cytosol of professional APCs for purified protein antigens, attenuated bacterial vaccine strains, DNA vaccines and liposome contents.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11166239     DOI: 10.1016/s0966-842x(00)01893-x

Source DB:  PubMed          Journal:  Trends Microbiol        ISSN: 0966-842X            Impact factor:   17.079


  8 in total

Review 1.  Dendritic cells: immune saviors or Achilles' heel?

Authors:  C W Cutler; R Jotwani; B Pulendran
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

2.  Cross-presentation of cell-associated antigens by CD8alpha+ dendritic cells is attributable to their ability to internalize dead cells.

Authors:  Oliver Schulz; Caetano Reis e Sousa
Journal:  Immunology       Date:  2002-10       Impact factor: 7.397

Review 3.  Liposomes as vaccine delivery systems: a review of the recent advances.

Authors:  Reto A Schwendener
Journal:  Ther Adv Vaccines       Date:  2014-11

4.  Tuberculosis vaccines: current progress.

Authors:  Ian M Orme
Journal:  Drugs       Date:  2005       Impact factor: 9.546

5.  Recombinant Listeria monocytogenes expressing a cell wall-associated listeriolysin O is weakly virulent but immunogenic.

Authors:  Javier A Carrero; Boris Calderon; Hector Vivanco-Cid; Emil R Unanue
Journal:  Infect Immun       Date:  2009-08-10       Impact factor: 3.441

6.  Novel Adjuvant Based on the Pore-Forming Protein Sticholysin II Encapsulated into Liposomes Effectively Enhances the Antigen-Specific CTL-Mediated Immune Response.

Authors:  Rady J Laborde; Oraly Sanchez-Ferras; María C Luzardo; Yoelys Cruz-Leal; Audry Fernández; Circe Mesa; Liliana Oliver; Liem Canet; Liane Abreu-Butin; Catarina V Nogueira; Mayra Tejuca; Fabiola Pazos; Carlos Álvarez; María E Alonso; Ieda M Longo-Maugéri; Michael N Starnbach; Darren E Higgins; Luis E Fernández; María E Lanio
Journal:  J Immunol       Date:  2017-03-03       Impact factor: 5.422

7.  Cancer immunotherapy targeting the high molecular weight melanoma-associated antigen protein results in a broad antitumor response and reduction of pericytes in the tumor vasculature.

Authors:  Paulo Cesar Maciag; Matthew M Seavey; Zhen-Kun Pan; Soldano Ferrone; Yvonne Paterson
Journal:  Cancer Res       Date:  2008-10-01       Impact factor: 12.701

8.  A Monoclonal Antibody against the C-Terminal Domain of Bacillus cereus Hemolysin II Inhibits HlyII Cytolytic Activity.

Authors:  Natalia Rudenko; Alexey Nagel; Anna Zamyatina; Anna Karatovskaya; Vadim Salyamov; Zhanna Andreeva-Kovalevskaya; Alexander Siunov; Alexander Kolesnikov; Anna Shepelyakovskaya; Khanafiy Boziev; Bogdan Melnik; Fedor Brovko; Alexander Solonin
Journal:  Toxins (Basel)       Date:  2020-12-19       Impact factor: 4.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.